Table 2 Treatment administration
Treatment administration | Group H | Group HP | P-value |
|---|---|---|---|
Targeted therapy cycles before surgery | N = 87 (%) | N = 55 (%) |  |
 4 | 48 (55.17) | 29 (52.73) | 0.913 |
 6 | 24 (27.59) | 17 (30.91) | |
 Others | 15 (17.24) | 9 (16.36) | |
Chemotherapy regimens before surgery | N = 87 (%) | N = 55 (%) |  |
 AC-T | 62 (71.26) | 36 (65.45) | 0.754 |
 TCb | 19 (21.84) | 14 (25.45) | |
 T | 6 (6.90) | 5 (9.09) | |
Breast surgery | N = 87 (%) | N = 55 (%) |  |
 Breast-conserving surgery | 3 (3.45) | 5 (9.09) | 0.261 |
 Mastectomy | 84 (96.55) | 50 (90.91) | |
Lymph node surgery | N = 87 (%) | N = 55 (%) |  |
 Sentinel node biopsy | 24 (27.59) | 17 (30.91) | 0.670 |
 Lymph node dissection | 63 (72.41) | 38 (69.09) | |
Treatment after surgery | N = 86 (%) | N = 55 (%) |  |
 Che + Targ + Rad | 27 (31.40) | 16 (29.09) | 0.886 |
 Endo + Targ + Rad | 23 (26.74) | 13 (23.64) |  |
 Che + Endo + Targ + Rad | 26 (30.23) | 16 (29.09) |  |
 Targ + Rad | 9 (10.47) | 8 (14.55) |  |
 Other | 1 (1.16) | 2 (3.64) |  |